Notably, ALDH2 deficiency partly reversed the up‐regulation of HO‐1 after CCl4 challenge, whereas administration of Alda‐1 could up‐regulate Nrf2/HO‐1 pathway as well as significantly decreased α‐SMA protein expression, which shed light on the application of Alda‐1 in clinical liver diseases. This evidence concerns the gene ACTA1 and liver disorder.